Med24
clinical-research 19. 10. 2026 • 2 min read • ClinicalTrials.gov (The University of Tennessee, Knoxville)

Families Becoming Healthy Together

The investigators plan to implement a novel limited RED (high-energy-dense) food variety prescription within a 18-month FBT to examine its effect on 18-month body mass index (BMI). This will be the first randomized control trial to examine how habituation rate, assessed via salivary habituation, mediates reduction in...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

The Families Becoming Healthy Together clinical trial is investigating the impact of a limited RED (high-energy-dense) food variety prescription within a 18-month Family-Based Therapeutic (FBT) intervention on body mass index (BMI) in children aged 8 to 12 years with a BMI greater than the 85th percentile. The study will compare FBT with FBT plus the limited variety prescription. One hundred fifty-six participants will be randomized to one of the two interventions. Assessments will occur at 0, 6, 12, and 18 months, measuring anthropometrics, dietary intake (RED food variety, energy, and diet quality), habituation, and physical activity. The intervention involves weekly group meetings for months 1-6, bi-monthly meetings for months 7-6, monthly meetings for months 7-12, and bi-monthly meetings for months 13-18. Meetings include feedback, homework review, and behavioral lessons, with separate 40-minute group and 20-minute individual therapist sessions. The study aims to determine the influence of FBT+Variety on long-term weight loss and habituation to RED foods, with habituation rate mediating differences in dietary intake and BMI. An exploratory aim is to examine if baseline habituation rate identifies a behavioral phenotype that benefits most from the limited variety prescription. Initial pilot data from 24 families showed a significantly greater reduction in percent overweight in the FBT+Variety group (-15.4%) compared to the FBT group (-8.9%), and a lower daily intake of kcal from fat (351 kcal vs. 494 kcal). Due to COVID-19, assessments and program meetings will occur remotely via Zoom. All intervention sessions and assessments will be conducted in person, with modifications implemented for health safety reasons.

Sponsored content

Original Scientific Source
ClinicalTrials.gov (The University of Tennessee, Knoxville)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation
clinical-research

Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation

The purpose of this study is to demonstrate the non-inferiority of the Equinox System with respect to iLux 2020. Approximately 120 participants are expected to take part in the research trial at a minimum of three (3) and up to five (5) sites across the United States. The expected duration of the study will be six (6)...

16. 11. 2026 Read article →
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C
clinical-research

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

16. 11. 2026 Read article →
Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity
clinical-research

Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity

Post-stroke upper limb spasticity is an important condition that negatively affects motor recovery, upper limb functions, and activities of daily living. Multimodal treatment approaches are recommended in the management of spasticity. In recent years, the effects of transcranial magnetic stimulation (TMS) on upper...

10. 11. 2026 Read article →
A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
clinical-research

A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells,...

10. 11. 2026 Read article →
Advertisement